May 12, 2026: The Centre of Excellence in Molecular Biology (CEMB) announced a significant step toward strengthening Pakistan’s biopharmaceutical sector through the technology transfer of the recombinant therapeutic product Filgrastim to leading national pharmaceutical companies The Searle Company and Ferozsons Laboratories.
The initiative is being carried out under the leadership and support of Federal minister for National Health Services, Research and Coordination, Syed Mustafa Kamal, Parliamentary Secretary Zulfiqar Ali Bhatti, CEO DRAP Dr. Obaidullah, and Chairman Licensing DRAP Dr. Noor Muhammad.
CEMB expressed its gratitude to the Federal Ministry of National Health Services and the Drug Regulatory Authority of Pakistan (DRAP) for their valuable support in facilitating the technology transfer process and promoting local biopharmaceutical manufacturing capabilities in Pakistan.
Filgrastim is an important therapeutic protein used as an immune booster in patients with depleted neutrophil counts, particularly cancer patients undergoing chemotherapy or radiation therapy. The drug helps stimulate white blood cell production and supports recovery of the immune system.
The announcement was made during an MoU signing ceremony held for API manufacturing and technology transfer, marking an important milestone toward enhancing indigenous production of advanced biologics in Pakistan.